Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 4/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12015 | 1.00 | CCR1 (0.41) | CCR1CCR5CCR8L3MBTL1LOX | |
| SCHEMBL27990718 | 0.98 | CCR1 (0.40) | CCR1CCR5CCR8L3MBTL1LOX | |
| Boric Acid SCHEMBL29053153 | 0.92 | TDP1 (0.38) | CCR1CCR5CCR8L3MBTL1LOX | |
| SCHEMBL21360044 | 0.92 | TDP1 (0.38) | CCR1CCR5CCR8L3MBTL1LOX | |
| SCHEMBL28115657 | 0.88 | MTNR1A (0.36) | CCR1CCR5CCR8L3MBTL1LOX | |
| SCHEMBL14394548 | 0.85 | CCR1 (0.38) | CCR1CCR5CCR8L3MBTL1LOX | |
| SCHEMBL12873555 | 0.81 | MAP4K1 (0.39) | CCR1CCR5CCR8L3MBTL1LOX | |
| SCHEMBL28020330 | 0.80 | TSHR (0.38) | CCR1CCR5CCR8L3MBTL1LOX | |
| SCHEMBL28020288 | 0.80 | MAPK8 (0.42) | LOXLOXL2LMNAMTNR1AMTNR1B | |
| SCHEMBL418747 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058790-A | Preparation method of novel phosphorus-containing agricultural compound synergist and application of novel phosphorus-containing agricultural compound synergist in agriculture | 贵州工业职业技术学院 | 2025-05-30 | — | — | CN | claimed |
| CN-118420548-A | Preparation method of 2, 4-dimethoxy-5-bromopyrimidine | 辽宁工程技术大学 | 2024-08-02 | — | — | CN | claimed |
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-04-02 | — | — | US | disclosed |
| CN-120058790-A | Preparation method of novel phosphorus-containing agricultural compound synergist and application of novel phosphorus-containing agricultural compound synergist in agriculture | 贵州工业职业技术学院 | 2025-05-30 | — | — | CN | disclosed |
| CN-120058790-A | Preparation method of novel phosphorus-containing agricultural compound synergist and application of novel phosphorus-containing agricultural compound synergist in agriculture | 贵州工业职业技术学院 | 2025-05-30 | — | — | CN | disclosed |
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2025-05-20 | — | — | US | disclosed |
| EP-4547657-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119751857-A | Non-isocyanate polyurea and preparation method thereof, water-based non-isocyanate polyurea and preparation method thereof, and anti-corrosion coating, waterproof coating and fireproof coating containing water-based non-isocyanate polyurea and preparation method thereof | 山西省建筑科学研究院集团有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119715887-A | Central control analysis method of high performance liquid chromatography in preparation process of 1, 3-dimethyl malonamidine dihydrochloride | 江苏丰山生化科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250092080-A1 | FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST VIRUSES | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2025-03-20 | — | — | US | disclosed |
| CN-110959138-B | Resist material | DIC株式会社 | 2023-06-30 | — | — | CN | disclosed |
| CN-111819173-B | CD73 inhibitors | 伊莱利利公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-2023077030-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-111566110-B | 1,2,3',5' -tetrahydro-2 ' H-spiro [ indole-3, 1' -pyrrolo [3,4-C ] pyrrole ] -2,3' -dione compounds as therapeutic agents for activating TP53 | 阿达梅德制药公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20220387434-A1 | COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT | QUOGUE IP HOLDINGS LLC (US) | 2022-12-08 | — | — | US | disclosed |
| CN-114585737-A | Oligonucleotide compositions and methods of use thereof | 波涛生命科学有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-112004845-B | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate, and semiconductor device | 三菱瓦斯化学株式会社 | 2022-05-31 | — | — | CN | disclosed |
| CN-114502548-A | Crystalline forms of a CD73 inhibitor | 伊莱利利公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-109232385-B | Preparation method of magnesium dichloride (2,2,6, 6-tetramethylpiperidine) lithium salt | 阜新孚隆宝医药科技有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | CCR1 3583/4885CCR5 4072/4885CCR8 2936/4885 |
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | SMG1, RACK1, TIA1 | CCR1 500/4885CCR5 2916/4885CCR8 2718/4885 |
| US-20250092080-A1 | FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST VIRUSES | FLNA, PNP, SMCHD1 | CCR1 751/4885CCR5 740/4885CCR8 143/4885 |
| US-20220387434-A1 | COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT | BTK, BCL9L, BCL9 | CCR1 3541/4885CCR5 3480/4885CCR8 3489/4885 |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, NRAS, RAF1 | CCR1 2960/4885CCR5 3249/4885CCR8 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.